Boston Biomedical Research Institute Inc

Biofyl Scientific Research, formerly known as BioSciences Research Associates, is an independent contract research laboratory based in Fort Myers, Florida. They specialize in providing scientific services to pharmaceutical and biotechnology companies, supporting activities related to product development and clinical trials. In addition to their core services, Biofyl conducts blood donation programs that contribute to regenerative medicine research, offering participants financial compensation for their contributions. The laboratory ensures strict confidentiality and ethical handling of donor information, maintaining robust security measures to protect participant identities. Generated from the website

The New England AIDS Education and Training Center (NEAETC) in Boston, MA, is dedicated to enhancing the knowledge and skills of healthcare providers in the field of HIV prevention, testing, and care. Through a variety of training programs and resources, NEAETC aims to improve patient outcomes and raise awareness about critical health concerns affecting those living with HIV and other related conditions. With partnerships across New England, including local health centers and academic institutions, NEAETC provides essential educational initiatives and updates on topics such as Hepatitis B infection and pre-exposure prophylaxis (PrEP). Funded by the U.S. Department of Health and Human Services, the center's mission is to support primary care providers in effectively addressing the complexities of HIV and viral hepatitis care. Generated from the website

Verastem Oncology, based in Boston, MA, is a biopharmaceutical company dedicated to developing innovative treatments for patients with RAS pathway-driven cancers. With a focus on mutations in the RAS family of genes, including KRAS, NRAS, and HRAS, Verastem Oncology aims to provide better options and outcomes for patients through targeted treatment combinations with avutometinib. Their research and development efforts are driven by a commitment to exploring uncharted paths and expanding possibilities for patients with difficult-to-treat cancers. Recognizing the significant impact of RAS pathway mutations on patient outcomes, Verastem Oncology is determined to ensure that no cancer patient runs out of options. By blocking multiple nodes in the RAS pathway, avutometinib, also known as VS-6766, has the potential to become a backbone of therapy when combined with other agents targeting the RAS pathway and parallel pathways involved in tumor growth and metastases. Through their relentless pursuit of innovative treatments, Verastem Oncology aims to provide patients with more choices and the hope of better outcomes.Generated from the website